Vertex INCIVEK sales likely to decline further, says Piper Jaffray

theflyonthewall.com

After the FDA forced Vertex to place a warning regarding fatal and non-fatal serious skin reactions on the boxes containing its INCIVEK HCV treatment, Piper Jaffray expects sales of the drug to decline further. The firm maintains a Neutral rating on the stock.

Rates

View Comments (0)